Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis

Area of Science:

• Oncology
• Immunohistochemistry
• Lymphoma Biology

Background:

• CD30 protein expression is crucial for lymphoma diagnosis, prognosis, and targeted therapy selection.
• Brentuximab vedotin (BV) utilizes CD30 as a target, highlighting the need for precise CD30 detection.
• Pathologists require consensus on CD30 testing and reporting for optimal patient care.

Purpose of the Study:

• To review indications for CD30 testing in lymphoma.
• To discuss various modalities and technical challenges in CD30 protein evaluation.
• To propose standards for reporting CD30 expression and address evaluation caveats.

Main Methods:

• Literature review of CD30 testing modalities and reporting structures.
• Analysis of technical challenges and potential pitfalls in CD30 assessment.
• Discussion of criteria for defining positive CD30 expression.

Main Results:

• CD30 testing is essential for diagnosis, prognosis, and guiding targeted therapies like BV.
• Varied testing modalities exist, each with specific technical challenges and interpretation nuances.
• Establishing clear reporting standards is necessary to ensure consistent and accurate patient management.

Conclusions:

• Standardized evaluation and reporting of CD30 protein expression are critical for lymphoma patient care.
• Addressing technical challenges and defining positive expression levels will improve diagnostic consistency.
• Consensus among pathologists on CD30 assessment methodologies is paramount for effective therapeutic strategies.